(NASDAQ: PETQ) Petiq's forecast annual revenue growth rate of 5.48% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 9.16%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.16%.
Petiq's revenue in 2024 is $1,101,963,000.On average, 4 Wall Street analysts forecast PETQ's revenue for 2024 to be $33,806,195,127, with the lowest PETQ revenue forecast at $33,257,389,340, and the highest PETQ revenue forecast at $34,375,779,424. On average, 4 Wall Street analysts forecast PETQ's revenue for 2025 to be $35,789,512,784, with the lowest PETQ revenue forecast at $35,023,268,420, and the highest PETQ revenue forecast at $36,288,815,094.
In 2026, PETQ is forecast to generate $38,290,144,718 in revenue, with the lowest revenue forecast at $38,290,144,718 and the highest revenue forecast at $38,290,144,718.